CALGARY,
AB, June 23, 2022 /CNW/ - Nanalysis
Scientific Corp. ("the Company", ("the Company",
TSXV: NSCI,
OTCQX: NSCIF,
FRA: 1N1), a leader in
portable NMR machines and MRI technology for healthcare and
industrial applications, is pleased to report that all proposed
resolutions were approved at the Company's Annual General and
Special Meeting of shareholders held on June
22, 2022 (the "Meeting"). The number of directors was set at
7 and all director nominees, as listed in the Management
Information Circular dated May 20,
2022 (the "Information Circular"), were elected as directors
of the Company at the Meeting to serve for a one-year term and hold
office until the next annual meeting of shareholders. According to
the proxy votes received from shareholders, the results were as
follows:
Nominees:
|
|
% For
|
|
%
Withheld
|
|
|
|
|
|
Sean
Krakiwsky
|
|
96.566 %
|
|
3.434 %
|
Martin
Burian
|
|
95.592 %
|
|
4.408 %
|
Werner
Gartner
|
|
99.852 %
|
|
0.148 %
|
Michal
Okoniewski
|
|
99.852 %
|
|
0.148 %
|
Guido
Cloetens
|
|
95.628 %
|
|
4.372 %
|
Rene
Lenggenhager
|
|
99.852 %
|
|
0.148 %
|
Kham
Lin
|
|
99.609 %
|
|
0.391 %
|
Shareholders voted 99.85% in favor of setting the number of
directors at seven, 99.6% in favor of appointing Ernst & Young
LLP, as auditor of the Company for the ensuing year and to
authorize the Directors of the Company to fix the auditor's
remuneration and 98.1% in favor for the approval of an amended
stock option plan of the Company.
Corporate Update
The Company is pleased to welcome Kham
Lin to Nanalysis's Board of Directors with immediate effect
following shareholder approval at the Meeting.
Mr. Lin is currently a Managing Director at Nanalysis and was
formerly the President and Chief Executive Officer of KPrime
Technologies before the Company's acquisition by Nanalysis.
Over twenty plus years, Mr. Lin built KPrime, into a manufacturing
representative business for global companies like Agilent
Technologies, Metrohm USA,
Sartorius LPS Division, and Leidos. KPrime has a portfolio of
sales and services in scientific detection and measuring equipment,
financing, and asset management for chemical and security
industries. Mr. Lin resides and works in Calgary, Alberta, Canada but also splits time
in Phoenix, Arizona at KPrime
Headquarters.
About Nanalysis Scientific
Corp. (TSXV: NSCI) (OTCQX: NSCIF)
(FRA:1N1)
Nanalysis trades on the TSX Venture Exchange (TSXV)
in Canada with ticker symbol 'NSCI', OTC and
the Frankfurt exchange under the ticker symbol '1N1'. The
company's business is what we term "MRI and NMR for industry". The
company develops and manufactures portable Nuclear Magnetic
Resonance (NMR) spectrometers or analyzers for laboratory and
industrial markets. The NMReady-60™ was the first full-feature
portable NMR spectrometer in a single compact enclosure requiring
no liquid helium or any other cryogens. The company has followed-up
that initial offering with new products and continues to have a
strong innovation pipeline. Nanalysis recently announced that it
has begun selling a 100MHz device in 2020. The Company's new device
will be the most powerful and most advanced compact NMR device ever
brought to market.
Nanalysis devices are used in many industries (oil and gas,
chemical, mining, pharma, biotech, flavor and fragrances,
agrochemicals, law enforcement, and more) as well as numerous
government and university research labs around the world. The
Company continues to exploit new global market opportunities
independently and with partners.
With the recent acquisition of K'Prime, the company maintains a
North American sales and service company of over 40 individuals who
cover scientific instrumentation for pharma, food, chemical and oil
& gas customers, as well as imaging systems for security
applications.
Additionally, the Company has a 43% ownership in Quad Systems AG
("Quad Systems"), with an option to purchase the remaining
shares. Quad Systems is a Zurich-based Nuclear Magnetic
Resonance (NMR) company focused on high-field NMR for
pharmaceutical and other vertical markets.
Notice regarding Forward Looking
Statements and Legal Disclaimer
This news release contains certain "forward-looking statements"
within the meaning of such statements under applicable securities
law. Forward-looking statements are frequently characterized by
words such as "anticipates", "plan", "continue", "expect",
"project", "intend", "believe", "anticipate", "estimate", "may",
"will", "potential", "proposed", "positioned" and other similar
words, or statements that certain events or conditions "may" or
"will" occur. These statements are only predictions. Various
assumptions were used in drawing the conclusions or making the
projections contained in the forward-looking statements throughout
this news release. Forward-looking statements are based on the
opinions and estimates of management at the date the statements are
made and are subject to a variety of risks and uncertainties and
other factors that could cause actual events or results to differ
materially from those projected in the forward-looking statements.
The Company is under no obligation, and expressly disclaims any
intention or obligation, to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as expressly required by applicable law.
Neither TSX Venture Exchange nor its Regulation Services
Provider accepts responsibility for the adequacy or accuracy of
this release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nanalysis-announces-results-of-agm-and-appointment-of-new-director-301574013.html
SOURCE Nanalysis Scientific Corp.